Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 17/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483296 | 0.94 | CHRM3 (0.45) | CHRM3ADRB2 | |
| SCHEMBL4489058 | 0.94 | ADRB2 (0.45) | CHRM3ADRB2EPHX2TMEM97 | |
| SCHEMBL4475453 | 0.93 | CHRM3 (0.43) | CHRM3ADRB2EPHX2TMEM97 | |
| SCHEMBL4478362 | 0.91 | CHRM3 (0.42) | CHRM3ADRB2 | |
| SCHEMBL4482057 | 0.91 | CHRM3 (0.48) | CHRM3ADRB2 | |
| SCHEMBL266188 | 0.90 | CHRM3 (0.55) | CHRM3ADRB2 | |
| SCHEMBL4480594 | 0.90 | SLC5A7 (0.43) | CHRM3ADRB2EPHX2TMEM97 | |
| SCHEMBL4483286 | 0.88 | CHRM3 (0.42) | CHRM3ADRB2EPHX2 | |
| SCHEMBL4489051 | 0.87 | ADRB2 (0.42) | CHRM3ADRB2EPHX2TMEM97 | |
| SCHEMBL4478187 | 0.86 | CHRM3 (0.40) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632847-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-15 | — | — | US | disclosed |